SequelSEC

iBio, Inc. IBIO

Pharmaceutical Preparations · CIK 0001420720 · Fiscal year ends 0630

Revenue
$100.00K
Fiscal year ended 2026-06-30
Operating income
-$35.14M
Fiscal year ended 2026-06-30
Free cash flow
-$23.80M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$57.51MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-12-31
Float per share$0.89Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue575.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2026-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue578.0%98th
FCF margin-23796.0%4th
R&D / revenue19643.0%95th
Operating margin-35141.0%6th
Net margin-33044.0%7th
SBC / revenue1373.0%90th
Revenue YoY growth-75.0%16th
Current ratio7.85x73th

iBio, Inc. (IBIO) reported revenue of $100.00K and net income of -$33.04M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from iBio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

iBio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$100.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$35.14M
Net income-$33.04M
Research & development$19.64M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$10.60M
Selling & marketingUnavailable

Balance

iBio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$56.40M
Total assets$99.11M
Current assets$92.22M
Total liabilities$13.40M
Current liabilities$11.74M
Total equity incl. NCI$85.71M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$4.42M

Cash flow

iBio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$23.22M
Capital expenditures$578.00K
Investing cash flow-$32.00M
Financing cash flow$103.05M
Net change in cash$47.83M
Stock-based compensation$1.37M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

iBio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$23.80M
Gross marginUnavailable
Operating margin-35141.0%
FCF margin-23796.0%
SBC / revenue1373.0%
Current ratio7.85x
Revenue YoY growth-75.0%
Net margin-33044.0%
R&D / revenue19643.0%
CapEx / revenue578.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IBIO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-08-28View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-Q · Filed 2026-02-10View SEC filing
10-Q/A · Filed 2025-11-17View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-K · Filed 2025-09-05View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.